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RUNX3 is believed to have tumour suppressor properties in several cancer types. Inactivation of RUNX3 has been shown to occur
by methylation-induced transcriptional silencing and by mislocalization of the protein to the cytoplasm. The aim of this study was to
examine the clinical significance of RUNX3 expression in a large series of colorectal cancers using immunohistochemistry and tissue
arrays. With advancing tumour stage, expression of RUNX3 in the nucleus decreased, whereas expression restricted to the
cytoplasmic compartment increased. Nuclear RUNX3 expression was associated with significantly better patient survival compared
to tumours in which the expression of RUNX3 was restricted to the cytoplasm (P¼0.025). These results support a role for RUNX3
as a tumour suppressor in colorectal cancer.
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The RUNX3 gene encodes a protein that belongs to the runt
domain family of transcription factors involved in mammalian
development pathways (Ito, 2008). RUNX3 protein can mediate the
growth suppressive effects of TGF-b by associating with SMAD, a
downstream protein in the signalling pathway (Ito and Miyazono,
2003). In RUNX3 knockout mice, the gastric epithelium displays
hyperplasia and a reduced sensitivity to TGF-b (Li et al, 2002). The
chromosomal locus for RUNX3 (1p36) shows frequent loss of
heterozygosity in a variety of cancer types including colon and
gastric carcinomas (Ito, 2008). In addition, mutations in RUNX3
have been shown in gastric (Li et al, 2002) and bladder (Kim et al,
2005) cancers. Recent work from our group has also shown that
RUNX3 protein forms a ternary complex with b-catenin/TCF4 (Ito
et al, 2008). This complex has reduced DNA-binding ability and
thus attenuates the level of signalling through the Wnt pathway.
The above findings suggest a putative tumour suppressor role for
RUNX3 in intestinal tumourigenesis.
Other studies have shown methylation-related transcriptional
silencing of RUNX3 expression in gastric (Li et al, 2002; Waki et al,
2003), colorectal (CRC) (Goel et al, 2004; Ku et al, 2004) and
oesophageal squamous cell (Sakakura et al, 2007) carcinomas. A
relatively high frequency of RUNX3 methylation has also been
observed in hepatocellular carcinoma and lung, breast and
prostate cancers (Kim et al, 2004). Mislocalisation of RUNX3
protein to the cytoplasm is another mechanism by which RUNX3
can be inactivated in gastric and breast cancers (Ito et al, 2005; Lau
et al, 2006). Overexpression of the enhancer of zeste homologue 2
(EZH2) protein was recently shown to downregulate RUNX3
expression by increasing histone H3 methylation, thus providing
yet another mechanism for inactivation of RUNX3 (Fujii et al,
2008). As might be expected, if RUNX3 were behaving as a tumour
suppressor, the decreased expression of this protein in gastric
(Wei et al, 2005), lung (Araki et al, 2005) and oesophageal
(Sakakura et al, 2007) cancers has been associated with worse
patient outcome.
As the TGF-b signalling pathway plays an important role in
the growth control of human colonic epithelial cells (Xu and
Pasche, 2007), RUNX3 may also act as a tumour suppressor
gene in this tissue. Approximately 20% of primary CRCs show
hypermethylation of RUNX3 (Goel et al, 2004; Ogino et al,
2007), and this has been linked to transcriptional silencing in two
studies (Goel et al, 2004; Ku et al, 2004). The high specificity of
RUNX3 methylation in tumour tissue relative to normal colonic
mucosa has led to its inclusion in a panel of five genes proposed
for the standardised classification of the CpG island methylator
phenotype (CIMP) in CRC (Weisenberger et al, 2006). Although it
is clear that methylation of the RUNX3 promoter region is one
of the ways in which this gene can be inactivated in CRC,
other mechanisms including mislocalisation of RUNX3 protein
could also be occurring. The expression of RUNX3 in CRC
as determined by immunohistochemistry has not previously
been reported. In this study, we used tissue microarrays containing
a very large number of primary CRC samples to investigate
the expression of RUNX3 in relation to tumour features and to
patient outcome.
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sMATERIALS AND METHODS
Tissue microarrays
Sections from tissue microarray (TMA) blocks containing 849 CRC
(stages I–IV) and matching normal tissue samples were obtained
from the West Australian Research Tissue Network, Department of
Radiation Oncology, Sir Charles Gairdner Hospital. Construction
of the TMAs and the tumour and patient characteristics have been
described elsewhere (Chai et al, 2004). Microsatellite instability
(MSI) status was determined using the BAT26 mononucleotide
marker as described previously (Chai et al, 2004). Ethics approval
to perform this study was obtained from the Human Research
Ethics Committee of the Sir Charles Gairdner Hospital.
Immunohistochemistry
Sections from tissue array blocks were cut at 5mm thickness and
stained for RUNX3 by immunohistochemistry using the mono-
clonal antibody clone R3-6E9 as described previously by our group
(Ito et al, 2005). The R3-6E9 clone recognises an epitope within the
191–234 amino-acid region. Its specificity for human RUNX3 has
been shown by Western blot analysis and by the removal of
immunoreactivity to normal gastric mucosa following preincuba-
tion with RUNX3 peptide (Ito et al, 2005). Rehydrated TMA
sections were warmed in target retrieval solution (DAKO,
Glostrup, Denmark) at 961C for 40min, treated with a serum-free
blocking solution (DAKO), and then incubated overnight at 41C
with 1mg/ml R3-6E9 in a diluent solution (DAKO). A peroxidase-3,
30-diaminobenzidine-based detection system (EnVisionþkit,
DAKO) was used to detect immunoreactivity. Staining was graded
for intensity on a scale of 0–4 in the nuclear and cytoplasmic
compartments. The scoring was performed by a single pathologist
(NS) following consultation with another pathologist (MST) and
in the absence of information on patient outcome or tumour
pathology. RUNX3 was considered to be expressed in the nucleus
or cytoplasm if the intensity was estimated at X2.
RESULTS AND DISCUSSION
Typically observed immunohistochemical staining patterns for
RUNX3 are shown in Figure 1. Using a staining intensity of X2a s
the threshold, RUNX3 expression was expressed in the nucleus of
631/849 (74%) tumours and in the cytoplasm of 431/849 (51%)
tumours. Both nuclear and cytoplasmic expressions were present
in 352 (41%) tumours, nuclear expression only in 279 (33%),
neither nuclear nor cytoplasmic expression in 139 (16%) and
cytoplasmic expression only in 79 (9%) tumours. In this study,
tumours with ‘any nuclear’ staining were considered to express
‘active’ RUNX3 (n¼631, Group A) (Lau et al, 2006). Tumours with
no nuclear or cytoplasmic staining (Group B) or with expression in
the cytoplasm only (Group C) were considered to have ‘inactive’
RUNX3.
The associations between RUNX3 expression and clinicopatho-
logical and molecular features of the CRC series are shown in
Table 1. No significant associations were seen with patient age or
gender, or with the histological grade of the tumour. Tumours
located in the proximal colon displayed a trend for less frequent
expression of nuclear RUNX3 compared to those arising in the
distal colon and rectum. A likely explanation for this finding is
that CIMPþ and RUNX3 methylation are known to occur more
often in the proximal colon (Weisenberger et al, 2006) and
are associated with methylation-induced transcriptional silencing.
The MSIþ phenotype is also closely associated with the CIMPþ
phenotype, thus accounting for the lower frequency of nuclear
RUNX3 expression observed in MSIþ tumours (Table 1).
In keeping with its postulated role as a tumour suppressor,
advanced stage tumours (AJCC stages III and IV) showed less
frequent expression of nuclear RUNX3 compared to early
stage tumours (Table 1). Kaplan–Meier analysis confirmed that
patients with nuclear RUNX3 expression (n¼631, Group A) had
significantly better survival outcomes (P¼0.025, logrank test)
compared to the relatively small number of patients (n¼79,
Group C) in which RUNX3 expression was restricted to the cyto-
plasm (Figure 2). This result agrees with observations made in
oesophageal cancer and is consistent with current understanding
of the role of RUNX3 as a tumour suppressor (Sakakura et al,
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Figure 1 Representative images showing expression of RUNX3 in the
nucleus only (A), in the cytoplasm only (B) and in both the nucleus and
cytoplasm (C). Images are at  40 magnification.
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our group to represent mislocalised and probably inactive protein
in gastric and breast cancers (Ito et al, 2005; Lau et al, 2006;
Subramaniam et al, 2009). The present results showing that
cytoplasmic expression is associated with worse patient outcome
support the contention that RUNX3 is in an inactive state.
Interestingly, the subgroup of CRC patients with no or very low
expression of RUNX3 in the nucleus or cytoplasm (Group B)
showed similar prognosis to those with nuclear RUNX3 expression
(Group A, Figure 2). This contrasts with several other cancer types
(Araki et al, 2005; Wei et al, 2005; Sakakura et al, 2007) and
suggests that the presence or absence of RUNX3 may play a lesser
role to its cytoplasmic localisation in determining clinical
phenotype in CRC. It should be highlighted, however, that two
of the earlier studies did not distinguish between nuclear and
cytoplasmic staining (Araki et al, 2005; Wei et al, 2005).
In summary, the major findings of this study were that nuclear
RUNX3 expression was reduced in advanced stages of CRC and
that exclusively cytoplasmic expression of RUNX3 was associated
with worse patient outcome.
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Figure 2 Kaplan–Meier survival analysis for CRC patients according to
the expression of RUNX3. (A) Any nuclear expression (n¼631); (B) no
nuclear or cytoplasmic expression (n¼139); (C) cytoplasmic expression
only (n¼79). Logrank test: A vs C, P¼0.025.
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